STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.
All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 10.3% and a median increase of 6.7%.
STERIS (STE) reported better-than-expected revenues for first-quarter fiscal 2022 on strong segmental performance driving the top line.
STERIS plc (STE) CEO Dan Carestio on Q1 2022 Results - Earnings Call Transcript
DUBLIN, IRELAND, Aug. 09, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 first quarter ended June 30, 2021. R
After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends that help to provide an income stre
Acquisitions of Cantel Medical and Key Surgical are expected to have contributed significantly to STERIS' (STE) first-quarter revenues.
DUBLIN, IRELAND , July 27, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2022 first quar

Five-Year Compounded Value of Steris Holdings

12:01pm, Friday, 02'nd Jul 2021
In a world obsessed with price movements of stocks, it's easy to lose sight of what those prices represent -- the value of holding a company's future profit potential. One of the key ways that profit
Steris (STE) reported earnings 30 days ago. What's next for the stock?
STERIS' (STE) acquisition of Cantel Medical will complement and broaden the former's product and service offerings, global reach and customers.
Investors are optimistic about STERIS (STE) owing to strong segmental performance and huge growth potential in healthcare and pharmaceutical industries.
NEW YORK, May 26, 2021 /PRNewswire/ -- S&P SmallCap 600 constituent Crocs Inc. (NASD:CROX) will replace Cantel Medical Corp. (NYSE:CMD) in the S&P MidCap 400, and Organogenesis Holdings Inc. (NASD: OR
STERIS plc (STE) CEO Walt Rosebrough on Q4 2021 Results - Earnings Call Transcript
STERIS' (STE) fourth-quarter 2021 revenues improved year over year on robust growth across three segments.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE